产品
编 号：F489823
分子式：C27H23N5O3
分子量：465.5
分子式：C27H23N5O3
分子量：465.5
产品类型
规格
价格
是否有货
结构图
CAS No: 871037-95-5
产品详情
生物活性：
TTT 3002 is a potent and orally active FLT3 inhibitor. TTT 3002 potently inhibits FLT3 phosphorylation by activating mutations at residue D835, with an IC50 of 0.2 nM. TTT 3002 can be used for AML (acute myeloid leukemia) research.
体内研究：
TTT 3002 (6 mg/kg，口服灌胃，每天两次，持续 2 至 4 周) 在体内对几种 FLT3/ITD 相关 AML 小鼠肿瘤模型有效，且毒性极小。TTT 3002 (6 mg/kg，口服灌胃，单次) 可被迅速吸收，具有双相最大血清浓度 (Cmax) 随后是单指数衰减。Animal Model:BALB/C mice (female, age 6 to 8 weeks, received Ba/F3-ITD Luc+ cells by tail vein injection on day 0)
Dosage:6 mg/kg
Administration:Oral gavage, twice per day, for 2 to 4 weeks
Result:Showed no significant changes in animal weight and was sufficient to eliminate the presence of Ba/F3-ITD Luc+ cells by day 17 (10 days of treatment).
Animal Model:Leukemic engrafted mice (female, age 6 to 8 weeks)
Dosage:6 mg/kg
Administration:Oral gavage, single (Pharmacokinetic Analysis)
Result:After oral administration, TTT 3002 was rapidly absorbed with a biphasic maximum serum concentration (Cmax) followed by a monoexponential decay. The Cmax and area under the concentration-time curve from time 0 to infinity (AUC0→∞) were 613 nM and 3127 nM?h, respectively. The half-life, apparent volume of distribution, and apparent clearance were 3.6 hours, 21 L/kg, and 4.1 L/h per kilogram, respectively.
体外研究：
TTT 3002 下调 Molm14 和 MV4-11 细胞中的 FLT3 磷酸化(pFLT3)。TTT 3002 诱导细胞周期停滞，随后显著诱导凋亡。
TTT 3002 is a potent and orally active FLT3 inhibitor. TTT 3002 potently inhibits FLT3 phosphorylation by activating mutations at residue D835, with an IC50 of 0.2 nM. TTT 3002 can be used for AML (acute myeloid leukemia) research.
体内研究：
TTT 3002 (6 mg/kg，口服灌胃，每天两次，持续 2 至 4 周) 在体内对几种 FLT3/ITD 相关 AML 小鼠肿瘤模型有效，且毒性极小。TTT 3002 (6 mg/kg，口服灌胃，单次) 可被迅速吸收，具有双相最大血清浓度 (Cmax) 随后是单指数衰减。Animal Model:BALB/C mice (female, age 6 to 8 weeks, received Ba/F3-ITD Luc+ cells by tail vein injection on day 0)
Dosage:6 mg/kg
Administration:Oral gavage, twice per day, for 2 to 4 weeks
Result:Showed no significant changes in animal weight and was sufficient to eliminate the presence of Ba/F3-ITD Luc+ cells by day 17 (10 days of treatment).
Animal Model:Leukemic engrafted mice (female, age 6 to 8 weeks)
Dosage:6 mg/kg
Administration:Oral gavage, single (Pharmacokinetic Analysis)
Result:After oral administration, TTT 3002 was rapidly absorbed with a biphasic maximum serum concentration (Cmax) followed by a monoexponential decay. The Cmax and area under the concentration-time curve from time 0 to infinity (AUC0→∞) were 613 nM and 3127 nM?h, respectively. The half-life, apparent volume of distribution, and apparent clearance were 3.6 hours, 21 L/kg, and 4.1 L/h per kilogram, respectively.
体外研究：
TTT 3002 下调 Molm14 和 MV4-11 细胞中的 FLT3 磷酸化(pFLT3)。TTT 3002 诱导细胞周期停滞，随后显著诱导凋亡。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备